Skip to main content

Table 1 Body weight and fasting blood glucose in WKY, WKY + SAL, GK, and GK + SAL rats in Experiment I, Experiment II, and Experiment III

From: Salidroside contributes to reducing blood pressure and alleviating cerebrovascular contractile activity in diabetic Goto-Kakizaki Rats by inhibition of L-type calcium channel in smooth muscle cells

 

20-week of age

24-week of age

(4 weeks SAL treatment)

Body weight (g)

Blood glucose (mM)

Body weight (g)

Blood glucose (mM)

Experiment I

 WKY(n = 10)

375.0 ± 11.5

5.2 ± 1.7

418.0 ± 18.8

5.2 ± 1.3

 WKY + 50 mg/kg/day SAL(n = 10)

383.8 ± 10.2

5.4 ± 1.3

409.5 ± 15.5

4.9 ± 1.8

 GK(n = 10)

389.0 ± 11.6

9.2 ± 2.4*

427.0 ± 12.3

11.6 ± 1.9*

 GK + 50 mg/kg/day SAL(n = 10)

391.0 ± 11.4

8.6 ± 2.1*

419.0 ± 18.9

10.2 ± 1.3*

Experiment II

 WKY(n = 15)

386.0 ± 15

5.26 ± 1.2

412.5 ± 17.8

5.8 ± 0.9

 WKY + 100 mg/kg/day SAL(n = 15)

378.5 ± 13

5.4 ± 2.2

426.9 ± 15.3

5.7 ± 1.2

 GK(n = 15)

392.0 ± 18

8.9 ± 1.3*

431.3 ± 16.3

10.5 ± 1.4*

 GK + 100 mg/kg/day SAL(n = 15)

387.0 ± 17

9.1 ± 1.6*

425.0 ± 11.2

7.8 ± 1.5#*

Experiment III

 WKY(n = 10)

378.0 ± 11.0

4.7 ± 1.5

408.0 ± 17.2

5.8 ± 1.6

 WKY + 200 mg/kg/day SAL(n = 10)

383.2 ± 13.6

5.2 ± 1.1

415.5 ± 16.5

3.4 ± 1.8*

 GK(n = 10)

389.0 ± 12.7

8.5 ± 1.2*

436.0 ± 12.7

11.2 ± 1.5*

 GK + 200 mg/kg/day SAL(n = 10)

393.0 ± 16.5

8.9 ± 1.0*

428.0 ± 15.2

8.1 ± 3.3#*

  1. WKY Control WKY rats, WKY + SAL WKY rats administrated with SAL, GK Diabetic GK rats, GK + SAL GK rats administrated with SAL. SAL was administrated with different dosage of 50, 100 and 200 mg/kg/day for 4 weeks in Experiment I, Experiment II, and Experiment III, respectively. *P < 0.05 vs. WKY and # P < 0.05 vs. GK rats